A detailed history of Royal Bank Of Canada transactions in Cerevel Therapeutics Holdings, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 4,020 shares of CERE stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,020
Previous 2,644 52.04%
Holding current value
$0
Previous $111,000 47.75%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$38.96 - $42.75 $53,608 - $58,824
1,376 Added 52.04%
4,020 $164,000
Q1 2024

May 15, 2024

SELL
$40.88 - $43.27 $816,986 - $864,750
-19,985 Reduced 88.32%
2,644 $111,000
Q4 2023

Feb 14, 2024

BUY
$20.27 - $42.44 $297,401 - $622,679
14,672 Added 184.39%
22,629 $959,000
Q3 2023

Nov 14, 2023

BUY
$20.26 - $31.91 $79,155 - $124,672
3,907 Added 96.47%
7,957 $173,000
Q2 2023

Aug 14, 2023

BUY
$23.9 - $35.38 $15,200 - $22,501
636 Added 18.63%
4,050 $128,000
Q1 2023

May 15, 2023

SELL
$22.82 - $35.32 $108,075 - $167,275
-4,736 Reduced 58.11%
3,414 $83,000
Q4 2022

Feb 14, 2023

BUY
$25.35 - $31.96 $131,591 - $165,904
5,191 Added 175.43%
8,150 $257,000
Q3 2022

Nov 14, 2022

BUY
$25.5 - $41.42 $12,240 - $19,881
480 Added 19.36%
2,959 $83,000
Q2 2022

Aug 15, 2022

SELL
$20.62 - $37.15 $45,240 - $81,507
-2,194 Reduced 46.95%
2,479 $66,000
Q1 2022

May 16, 2022

SELL
$23.5 - $35.38 $336,167 - $506,110
-14,305 Reduced 75.38%
4,673 $164,000
Q4 2021

Feb 14, 2022

BUY
$29.21 - $44.64 $395,853 - $604,961
13,552 Added 249.76%
18,978 $615,000
Q3 2021

Nov 15, 2021

BUY
$21.26 - $38.85 $64,035 - $117,016
3,012 Added 124.77%
5,426 $160,000
Q2 2021

Aug 16, 2021

BUY
$12.56 - $29.69 $30,319 - $71,671
2,414 New
2,414 $62,000

Others Institutions Holding CERE

About Cerevel Therapeutics Holdings, Inc.


  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.